NCT05954897RecruitingPhase 2
Lenvatinib, Tislelizumab Combined With RALOX Regimen HAIC in Advanced Hepatocellular Carcinoma: a Phase II, Single-arm, Prospective Study
Guangdong Provincial People's Hospital1 site in 1 country29 target enrollmentStarted: September 1, 2023Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Recruiting
- Enrollment
- 29
- Locations
- 1
- Primary Endpoint
- Objective Response Rate
Study Overview
Brief Summary
To evaluate the efficacy and safety of lenvatinib, tislelizumab combined with RALOX regimen HAIC in advanced hepatocellular carcinoma.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •18 years or older.
- •HCC was diagnosed according to the Criteria for Diagnosis and Treatment of Primary Liver Cancer (2022 Edition) and American Association for the Study of Liver Diseases (AASLD) criteria.
- •Classified as stage C according to the Barcelona Clinic Liver Cancer (BCLC) staging system.
- •A dominant mass in theliver with or without extrahepatic oligometastasis, which was defined as up to three metastatic lesions in up to two organs with the largest diameter of≤3 cm.
- •No prior treatment for HCC.
- •At least one measurable target lesion according to modified Response Evaluation Criteria in Solid Tumors (mRECIST).
- •Performance status (PS) ECOG score ≤
- •Child-Pugh score ≤
- •Subjects voluntarily participate in this study, and sign the informed consent form, cooperate with the follow-up
- •Adequate organ function, defined as: Hb ≥ 90 g/dL; Neu ≥ 1.5 x 10 ^ 9/L; PLT ≥ 75 x 10 ^ 9/L; ALB ≥2.8 g/dL; TBIL ≤2 times the upper limit of normal; AST and ALT ≤ 3 times the upper limit of normal; Cre ≤1.5 x upper limit of normal; APTT≤1.5 times the upper limit of normal.
Exclusion Criteria
- •Pathologically confirmed diagnosis of fibrolamellar HCC, sarcomatoid HCC, hepatocellular carcinoma-intrahepatic cholangiocarcinoma (HCC-ICC) mixed type;
- •Previous liver transplantation;
- •History of other malignancies;
- •Previous history of severe mental illness;
- •Uncontrollable hepatic encephalopathy, hepatorenal syndrome, ascites, pleural effusion or pericardial effusion;
- •Active bleeding or coagulation abnormalities, bleeding tendency or receiving thrombolytic, anticoagulant or antiplatelet therapy;
- •Other reasons were judged by the investigator to be unable to enroll.
Arms & Interventions
Experimental group
Experimental
Intervention: Lenvatinib, Tislelizumab Combined with RALOX Regimen HAIC (Drug)
Outcomes
Primary Outcomes
Objective Response Rate
Time Frame: After the first HAIC treatment, until the disease progresses or dies (during the treatment of the patient) or the toxicity is intolerable，through study completion, an average of 12 months
The proportion of patients whose tumors have shrunk to a certain amount and maintained for a certain period of time, including cases of complete remission (CR), partial remission (PR) under mRECIST criteria
Secondary Outcomes
- Disease control rate(From date of the first HAIC treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months)
- Overall survival(Through study completion, up to 24 months)
- Progression-free survival(From date of the first HAIC treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months)
- Adverse Events(Until the last medication for 30 days (±7 days) or before the start of other anti-tumor therapy (whichever occurs first).)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Not yet recruiting
Phase 2
The Efficacy and Safety of Tislelizumab Combined With Anlotinib and S1 Plus Oxaliplatin as Neoadjuvant Therapy for the Locally Advanced Adenocarcinoma of Esophagogastric JunctionImmunotherapy Gastroesophageal JunctionNCT06396585Fujian Cancer Hospital28
Completed
Phase 1
Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast CancerBreast CarcinomaHER-2 Positive Breast CancerMetastatic Breast CancerNCT02066532Dawn L. Hershman32
Recruiting
Phase 2
TACE/HAIC Combined With Lenvatinib and Sintilimab in Neoadjuvant Therapy for Intermediate-stage HCCHepatocellular CarcinomaNCT05250843Third Affiliated Hospital, Sun Yat-Sen University90
Completed
Phase 2
First-line Apatinib Combined With Tislelizumab and Chemotherapy for Advanced GCAdvanced Gastric AdenocarcinomaNCT06238752Renmin Hospital of Wuhan University33
Recruiting
Phase 2
Ruxolitinib With Tacrolimus and Methotrexate for the Prevention of Graft Versus Host Disease in Pediatric and Young Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic SyndromeAcute Myeloid LeukemiaAcute Lymphoblastic LeukemiaMyelodysplastic SyndromeNCT06128070City of Hope Medical Center40